7S9 is the first-in-class chemical inhibitor of KIF2C. By blocking microtubule depolymerization, 7S9 disrupts mitosis and induces apoptosis in chemoresistant cancer cells. 7S9 shows excellent cell penetration and cytotoxicity, boosting the efficacy of various chemotherapeutic agents by 5- to 200-fold. As the only chemosensitizer with high combination potential, 7S9 holds promising therapeutic impacts across female cancers.

7S9 is the first cell-permeable, KIF2C-specific small-molecule inhibitor with intrinsic cytotoxic activity, overcoming the cell-impermeability barrier of prior KIF2C inhibitors. It synergizes with 8 of 14 chemotherapies, achieving 5- to 200-fold potentiation in paclitaxel-resistant tumors. Because KIF2C is overexpressed in >75% of solid tumors and 95% of TNBC, 7S9 acts as a broadly applicable chemo-sensitizer requiring no companion diagnostic, redefining tumor multidrug-resistance therapy.

Targeting the global $12.8 billion TNBC market, 7S9 is the only chemosensitizer on the market that combines high formulation compatibility with broad applicability, effectively enhancing the efficacy of chemotherapeutic agents. 7S9 can be developed as an oral drug and, in the future, expanded to multiple gynecologic cancers. Therefore, the application of 7S9 in tumor multidrug resistance holds substantial niche value and commercial opportunity, contributing to improved patient survival rates.